Alkermes plc (ALKS) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to the Alkermes First Quarter twenty twenty six Financial Results Conference Call. My name is Carrie, and I will be your operator for today's call. All participant lines will be placed on mute to prevent background noise. Please note this conference is being recorded. I will now turn the call over to Sandra Coombs, Senior Vice President of Investor Relations and Corporate Affairs. Sandy, you may now begin. Good morning. Welcome to the Alkermes plc conference call to discuss our financial results and business update for the quarter ended 03/31/2026. With me today are Richard Pops, our CEO Joshua Reed, our Chief Financial Officer Todd Nichols, our Chief Commercial Officer and Blair Jackson, our Chief Operating Officer. A slide presentation along with our press release, related financial tables and reconciliations of the GAAP to non GAAP financial measures that we'll discuss today are available on the Investors section of alkermes.com. We believe the non GAAP financial results in conjunction with the GAAP results are useful in understanding the ongoing economics of our business. During the quarter, we closed the acquisition of Avadel Pharmaceuticals plc. The financial results announced today reflect the mid February closing of the transaction and the integration of Avadel into our business, including six weeks of contribution from Lumerize, Avadel's once at bedtime sodium oxybate for the treatment of narcolepsy. Our discussions during this conference call will include forward looking statements. Actual results could differ materially from these forward looking statements. Please see slide two of the accompanying presentation, our press release issued this morning, and our most recent annual report filed with the SEC for important risk factors that...